CBS 2019
CBSMD教育中心
中 文

科学研究

Abstract

Recommended Article

The Year in Cardiovascular Medicine 2020: Coronary Intervention Safety and feasibility of robotic percutaneous coronary intervention: PRECISE (Percutaneous Robotically-Enhanced Coronary Intervention) Study AIM2-driven inflammasome activation in heart failure Residual Inflammatory Risk in Patients With Low LDL Cholesterol Levels Undergoing Percutaneous Coronary Intervention Timing and Causes of Unplanned Readmissions After Percutaneous Coronary Intervention: Insights From the Nationwide Readmission Database Impact of Statins on Cardiovascular Outcomes Following Coronary Artery Calcium Scoring Effect of Side Branch Predilation in Coronary Bifurcation Stenting With the Provisional Approach - Results From the COBIS (Coronary Bifurcation Stenting) II Registry PCI and CABG for Treating Stable Coronary Artery Disease

Review Article2017 Jul 18;70(3):389-398.

JOURNAL:J Am Coll Cardiol. Article Link

Implantable Hemodynamic Monitoring for Heart Failure Patients

Abraham WT, Perl L. Keywords: disease management; hospitalization; patient readmission; pulmonary artery pressure; telemedicine

ABSTRACT


Rates of heart failure hospitalization remain unacceptably high. Such hospitalizations are associated with substantial patient, caregiver, and economic costs. Randomized controlled trials of noninvasive telemedical systems have failed to demonstrate reduced rates of hospitalization. The failure of these technologies may be due to the limitations of the signals measured. Intracardiac and pulmonary artery pressure-guided management has become a focus of hospitalization reduction in heart failure. Early studies using implantable hemodynamic monitors demonstrated the potential of pressure-based heart failure management, whereas subsequent studies confirmed the clinical utility of this approach. One large pivotal trial proved the safety and efficacy of pulmonary artery pressure-guided heart failure management, showing a marked reduction in heart failure hospitalizations in patients randomized to active pressure-guided management. "Next-generation" implantable hemodynamic monitors are in development, and novel approaches for the use of this data promise to expand the use of pressure-guided heart failure management.